Show notes
AMG 160; a half-life extended (HLE) bispecific T-cell engager (BITE®) antibody construct is discussed as is the future of immune therapy in CRPC.
AMG 160; a half-life extended (HLE) bispecific T-cell engager (BITE®) antibody construct is discussed as is the future of immune therapy in CRPC.